Mostrar el registro sencillo del ítem

dc.contributor.authorMorales Zamora, Gilberto Andres
dc.contributor.authorEspinosa, Oscar
dc.contributor.authorPuertas, Edwin
dc.contributor.authorFernández, Juan Carlos
dc.contributor.authorHernández, José
dc.contributor.authorZakzuk, Verónica
dc.contributor.authorCepeda, Magda
dc.contributor.authorAlvis Guzmán, Nelson
dc.contributor.authorCastañeda-Orjuela, Carlos
dc.contributor.authorPaternina, Angel
dc.coverage.spatialColombia
dc.date.accessioned2022-09-29T13:28:53Z
dc.date.available2022-09-29T13:28:53Z
dc.date.issued2022-05-26
dc.date.submitted2022-09-28
dc.identifier.citationGilberto Morales-Zamora, Oscar Espinosa, Edwin Puertas, Juan Carlos Fernández, José Hernández, Verónica Zakzuk, Magda Cepeda, Nelson Alvis-Gúzman, Carlos Castañeda-Orjuela, Angel Paternina-Caicedo, Cost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Plan, Value in Health Regional Issues, Volume 31, 2022, Pages 101-110, ISSN 2212-1099, https://doi.org/10.1016/j.vhri.2022.04.004.spa
dc.identifier.urihttps://hdl.handle.net/20.500.12585/11123
dc.description.abstractObjectives: Our study compares two national COVID-19 vaccination plan strategies—high-risk prioritization and no prioritization—and estimates their cost-effectiveness compared with no vaccination, to generate possible recommendations for future vaccination plans. Methods: We developed a Markov discrete-time, compartmental, deterministic model stratified by Colombian departments, healthcare workers, comorbidities, and age groups and calibrated to seroprevalence, cases, and deaths. The model simulates three scenarios: no vaccination, no prioritization of vaccination, and prioritization of high-risk population. The study presents the perspective of the health system of Colombia, including the direct health costs financed by the government and the direct health outcomes related to the infection. We measured symptomatic cases, deaths, and costs for each of the three scenarios from the start of the vaccination rollout to February 20, 2023. Results: Both for the base-case and across multiple sensitivity analyses, the high-risk prioritization proves to be the most cost effective of the considered strategies. An increment of US$255 million results in an incremental cost-effectiveness ratio of US$3339 per disability-adjusted life-year avoided. The simulations show that prioritization of high-risk population reduces symptomatic cases by 3.4% and deaths by 20.1% compared with no vaccination. The no-prioritization strategy is still cost effective, with an incremental cost-effectiveness ratio of US$5223.66, but the sensitivity analysis the show potential risks of losing cost-effectiveness under the cost-effectiveness threshold (one gross domestic product per averted disability adjusted life-year). Conclusions: The high-risk prioritization strategy is consistently more cost-effective than the no-prioritization strategy across multiple scenarios. High-risk prioritization is the recommended strategy in low-resource settings to reduce the burden of disease.spa
dc.format.extent10 Páginas
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleCost-Effectiveness Analysis of Strategies of COVID-19 Vaccination in Colombia: Comparison of High-Risk Prioritization and No Prioritization Strategies With the Absence of a Vaccination Planspa
dcterms.bibliographicCitationE. Dong, H. Du, L. Gardner An interactive web-based dashboard to track COVID-19 in real time Lancet Infect Dis, 20 (5) (2020), pp. 533-534 [published correction appears in Lancet Infect Dis. 2020;20(9):e215]spa
dcterms.bibliographicCitationN. Davies, A. Kucharski, R. Eggo, A. Gimma, W. Edmunds Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study Lancet Public Health, 5 (7) (2020), pp. e375-e385spa
dcterms.bibliographicCitationS. Flaxman, S. Mishra, A. Gandy, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe Nature, 584 (7820) (2020), pp. 257-261spa
dcterms.bibliographicCitationM. Voysey, S. Clemens, S. Madhi, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of 4 randomised controlled trials in Brazil, South Africa, and the UK Lancet, 397 (10269) (2021), pp. 99-111spa
dcterms.bibliographicCitationL. Baden, H. El Sahly, B. Essink, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med, 384 (5) (2021), pp. 403-416spa
dcterms.bibliographicCitationN. Dagan, N. Barda, E. Kepten, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting N Engl J Med, 384 (15) (2021), pp. 1412-1423spa
dcterms.bibliographicCitationF. Polack, S. Thomas, N. Kitchin, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N Engl J Med, 383 (27) (2020), pp. 2603-2615spa
dcterms.bibliographicCitationM. Knoll, C. Wonodi Oxford–AstraZeneca COVID-19 vaccine efficacy Lancet, 397 (10269) (2021), pp. 72-74spa
dcterms.bibliographicCitationQ. Li, X. Guan, P. Wu, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia N Engl J Med, 382 (13) (2020), pp. 1199-1207spa
dcterms.bibliographicCitationGlobal economic prospects. Resumen. https://www.bancomundial.org/es/publication/global-economic-prospects. Accessed December 23, 2020.spa
dcterms.bibliographicCitationInstitute for Health Metrics and Evaluation University of Washington. Healthdata – Global Burden of Disease, University of Washington (2021) https://vizhub.healthdata.org/gbd-results/spa
dcterms.bibliographicCitationMinisterio de Salud y Protección Social Base de Datos Única de Afiliados (BDUA). 2012-2020;Vol 2020 https://servicios.adres.gov.co/BDUA/Consulta-Afiliados-BDUAspa
dcterms.bibliographicCitationMinisterio de Salud y Protección Social Departamento Administrativo Nacional de Estadística. Estadísticas Vitales. 2012-2019;Vol 2020 https://www.dane.gov.co/index.php/servicios-al-ciudadano/281-demograficas/estadisticas-vitalesspa
dcterms.bibliographicCitationA. Briggs, K. Claxton, M. Sculpher Decision modelling for health economic evaluation Oxford University Press, Oxford, United Kingdom (2006)spa
dcterms.bibliographicCitationMinisterio de Salud y Protección Social. Base de datos de la Suficiencia del Aseguramiento en Salud. Vol. 2021; 2012-2018.spa
dcterms.bibliographicCitationMinisterio de Salud y Protección Social Base de Datos del Registro Único Nacional de Talento Humano en Salud. (ReTHUS). 2020 https://web.sispro.gov.co/THS/Cliente/ConsultasPublicas/ConsultaPublicaDeTHxIdentificacion.aspxspa
dcterms.bibliographicCitationR. Verity, L. Okell, I. Dorigatti, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis Lancet Infect Dis, 20 (6) (2020), pp. 669-677 [published correction appears in Lancet Infect Dis. 2020;20(6):e116]spa
dcterms.bibliographicCitationInstituto Nacional de Salud Base de datos de Casos. COVID-19 en Colombia; 2020 https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspxspa
dcterms.bibliographicCitationK. Prem, A. Cook, M. Jit Projecting social contact matrices in 152 countries using contact surveys and demographic data PLoS Comput Biol, 13 (9) (2017), Article e1005697spa
dcterms.bibliographicCitationGoogle. COVID-19 Community Mobility Reports https://www.google.com/covid19/mobility/spa
dcterms.bibliographicCitationMutual Ser EPS. Mutual Ser EPS COVID-19 recorded cases. 2020.spa
dcterms.bibliographicCitationDepartamento Administrativo Nacional de Estadística Producto Interno Bruto – Datos actualizados para Vol. 2021 (2020) https://www.dane.gov.co/index.php/estadisticas-por-tema/cuentas-nacionales/cuentas-nacionales-trimestrales/pib-informacion-tecnicaspa
dcterms.bibliographicCitationDepartamento Administrativo Nacional de Estadística (Ed.), Censo Nacional de Poblacion y Vivienda 2018, Departamento Administrativo Nacional de Estadística (2018) https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/censo-nacional-de-poblacion-y-vivenda-2018spa
dcterms.bibliographicCitationJ. Nelder, R. Mead A simplex method for function minimization Comput J, 7 (4) (1965), pp. 308-313spa
dcterms.bibliographicCitationY. Huang, W. McColl Improved simplex method for function minimization Proc IEEE Int Conf Syst Man Cybern, 3 (1996), pp. 1702-1705spa
dcterms.bibliographicCitationN. Davies, S. Abbott, R. Barnard, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Science, 372 (6538) (2021)spa
datacite.rightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.hasversioninfo:eu-repo/semantics/restrictedAccessspa
dc.identifier.doihttps://doi.org/10.1016/j.vhri.2022.04.004
dc.subject.keywordsColombiaspa
dc.subject.keywordsCost-effectivenessspa
dc.subject.keywordsModelingspa
dc.subject.keywordsSevere acute respiratory syndrome coronavirus 2spa
dc.subject.keywordsVaccinationspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.ccAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.instnameUniversidad Tecnológica de Bolívarspa
dc.identifier.reponameRepositorio Universidad Tecnológica de Bolívarspa
dc.publisher.placeCartagena de Indiasspa
dc.subject.armarcLEMB
dc.type.spahttp://purl.org/coar/resource_type/c_2df8fbb1spa
oaire.resourcetypehttp://purl.org/coar/resource_type/c_2df8fbb1spa


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

http://creativecommons.org/licenses/by-nc-nd/4.0/
http://creativecommons.org/licenses/by-nc-nd/4.0/

Universidad Tecnológica de Bolívar - 2017 Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional. Resolución No 961 del 26 de octubre de 1970 a través de la cual la Gobernación de Bolívar otorga la Personería Jurídica a la Universidad Tecnológica de Bolívar.